Natriuretic Peptides and Sodium: The Kidney Link

Kidney & Fluid Balance Peptides

3 natriuretic peptides

ANP, BNP, and CNP form a peptide system that directly opposes the renin-angiotensin-aldosterone system to promote sodium excretion and lower blood pressure.

Potter et al., Endocrine Reviews, 2009

Potter et al., Endocrine Reviews, 2009

View as image

Your kidneys filter about 180 liters of fluid per day, reabsorbing roughly 99% of it. The balance between what gets reabsorbed and what gets excreted as urine is controlled, in large part, by competing peptide systems. On one side, the renin-angiotensin-aldosterone system (RAAS) promotes sodium and water retention. On the other, natriuretic peptides promote sodium excretion (natriuresis) and water loss (diuresis).^[1] For the pillar article on fluid balance peptides, see vasopressin and water reabsorption. For the opposing system, see how the renin-angiotensin system controls your kidneys.

This article explains how atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) act on the kidney to regulate sodium balance, and what happens when this system malfunctions.

The Three Natriuretic Peptides

ANP, BNP, and CNP share a common 17-amino acid ring structure formed by a disulfide bond, but they differ in origin, receptor affinity, and primary function.

ANP (Atrial Natriuretic Peptide): A 28-amino acid peptide released from atrial cardiomyocytes when the atria stretch due to increased blood volume. ANP is the primary natriuretic peptide acting on the kidney. It was discovered in 1981 when de Bold et al. showed that atrial extracts caused rapid natriuresis and diuresis in rats.^[1] For more on ANP's cardiovascular effects, see ANP: the atrial peptide that lowers blood pressure.

BNP (B-type Natriuretic Peptide): A 32-amino acid peptide released primarily from ventricular cardiomyocytes in response to volume overload and pressure stress. BNP has natriuretic activity similar to ANP but is better known clinically as a heart failure biomarker. For diagnostic applications, see BNP and NT-proBNP as heart failure biomarkers.

CNP (C-type Natriuretic Peptide): A 22-amino acid peptide produced mainly by endothelial cells and the central nervous system. CNP binds a different receptor (NPR-B rather than NPR-A) and has minimal direct natriuretic activity. Its primary actions are vascular relaxation and bone growth regulation.

Potter et al. (2009) provided a comprehensive review of natriuretic peptide structures, receptors, and functions, noting that ANP and BNP signal through NPR-A to produce cGMP as a second messenger, while CNP signals through NPR-B.^[2] A third receptor, NPR-C, acts as a clearance receptor that removes natriuretic peptides from the circulation. Neprilysin, an ectoenzyme, also degrades them.

How ANP Promotes Sodium Excretion

ANP's natriuretic effect in the kidney operates through multiple mechanisms, occurring at different points along the nephron and involving both direct tubular effects and indirect hemodynamic changes.

Tubular Effects

Beltowski and Wojcicka (2002) reviewed two decades of research on how natriuretic peptides regulate renal tubular sodium transport. ANP's primary site of action is the inner medullary collecting duct (IMCD), the final segment where sodium reabsorption can be regulated before urine enters the renal pelvis.^[3]

In the IMCD, ANP inhibits sodium reabsorption through two coordinated actions. On the apical (urine-facing) membrane, it inhibits the epithelial sodium channel (ENaC), the channel through which sodium enters the collecting duct cell from the tubular fluid. On the basolateral (blood-facing) membrane, it inhibits the Na+/K+-ATPase pump, which normally drives sodium out of the cell into the interstitium. By blocking both the entry and exit of sodium from the collecting duct cell, ANP effectively shuts down sodium reabsorption at this critical site.

The signaling pathway is: ANP binds NPR-A on the collecting duct cell surface, activating guanylyl cyclase, which produces cGMP. cGMP activates protein kinase G (PKG-II), which phosphorylates and inhibits ENaC. This mechanism was confirmed by Silver (2006), who noted that cGMP is the universal second messenger for natriuretic peptide signaling in the kidney.^[4]

Hemodynamic Effects

Wong et al. (2017) reviewed the renal hemodynamic effects of natriuretic peptides. ANP increases glomerular filtration rate (GFR) by dilating the afferent arteriole (the vessel bringing blood into the glomerulus) while constricting the efferent arteriole (the vessel carrying blood away).^[5] This combination increases the pressure gradient across the glomerular capillaries, forcing more fluid through the filtration barrier. More filtration means more sodium in the tubular fluid, which contributes to natriuresis even before tubular reabsorption is inhibited.

ANP also increases blood flow to the renal medulla, the deeper part of the kidney where the collecting ducts reside. This medullary "washout" effect reduces the concentration gradient that normally drives water reabsorption, contributing to diuresis alongside natriuresis.

Opposing the Renin-Angiotensin-Aldosterone System

Natriuretic peptides and the RAAS operate as physiological antagonists. Silver (2006) described how natriuretic peptides suppress the RAAS at three distinct points.^[4]

Renin: ANP directly inhibits renin secretion from juxtaglomerular cells, reducing the production of angiotensin I and, downstream, angiotensin II. Since angiotensin II is the primary stimulus for sodium reabsorption in the proximal tubule and aldosterone release from the adrenal cortex, inhibiting renin has cascading anti-sodium effects throughout the RAAS.

Aldosterone: ANP directly inhibits aldosterone secretion from the adrenal glomerulosa, independent of its effect on renin. Aldosterone normally stimulates ENaC expression in the collecting duct, so reduced aldosterone means fewer sodium channels available for reabsorption.

Angiotensin II effects: Even when angiotensin II is present, ANP can counteract its tubular effects by activating cGMP-dependent pathways that oppose angiotensin II-driven sodium reabsorption.

This triple suppression makes the natriuretic peptide system a comprehensive counter-regulatory mechanism. When blood volume increases and the heart stretches, ANP release simultaneously promotes sodium excretion and suppresses the system that would otherwise retain it. For a detailed look at the competing system, see how the renin-angiotensin system controls your kidneys.

BNP and the Heart-Kidney Axis

BNP is both a natriuretic peptide and a biomarker, and these dual roles intersect at the kidney.

Okamoto et al. (2019) reviewed BNP as a major player in the heart-kidney connection. BNP is released from ventricular cardiomyocytes when the heart is under pressure or volume stress. It acts on the kidney through the same NPR-A receptor as ANP, promoting natriuresis and diuresis. But BNP is also cleared by the kidney (through NPR-C and neprilysin), creating a feedback loop: kidney dysfunction reduces BNP clearance, elevating plasma levels even without worsening heart failure.^[6]

This creates a clinical problem. BNP and its inactive fragment NT-proBNP are widely used to diagnose and monitor heart failure. But in patients with chronic kidney disease, BNP levels are elevated due to reduced renal clearance, hypervolemia, and hypertension. This makes it difficult to distinguish whether an elevated BNP reflects cardiac dysfunction, renal dysfunction, or both. For clinical applications, see BNP and NT-proBNP heart failure blood tests.

Despite this diagnostic complexity, Okamoto et al. argued that BNP has genuine protective effects in kidney disease. BNP counteracts the RAAS, reduces cardiac remodeling, and promotes fluid unloading. The peptide sacubitril/valsartan (Entresto), which blocks neprilysin to increase natriuretic peptide levels while also blocking the angiotensin receptor, has shown kidney-protective effects in heart failure trials. See sacubitril/valsartan for how this drug leverages the natriuretic peptide system.

Urodilatin: The Kidney's Own Natriuretic Peptide

The kidney produces its own natriuretic peptide. Urodilatin is a 32-amino acid peptide derived from the same precursor as ANP (pro-ANP) but processed differently by the kidney's distal tubular cells. Instead of being released into the bloodstream, urodilatin is secreted into the tubular lumen, where it acts locally to regulate sodium excretion.^[2]

Bie and Damkjaer (2018) reviewed how natriuretic peptides, including urodilatin, contribute to normal body fluid regulation. They noted that urodilatin may serve as a fine-tuning mechanism for sodium balance, acting on a faster timescale than circulating ANP and allowing the kidney to adjust sodium excretion in response to local conditions without relying entirely on systemic signals from the heart.^[1]

Urodilatin is resistant to degradation by neprilysin, giving it a longer local half-life in the kidney than circulating ANP. This property has made synthetic urodilatin (ularitide) a candidate for therapeutic use in acute heart failure, where rapid natriuresis is needed.

When the System Fails

Natriuretic peptide resistance, a state where elevated peptide levels fail to produce adequate natriuresis, occurs in several disease states.

In heart failure, natriuretic peptide levels rise dramatically as the failing heart stretches, but sodium retention persists. This paradox reflects multiple mechanisms: downregulation of NPR-A receptors in the kidney, increased neprilysin activity that degrades circulating peptides, enhanced RAAS activation that overwhelms natriuretic peptide effects, and reduced renal blood flow that limits peptide delivery to target nephron segments.

In chronic kidney disease, the loss of functional nephrons reduces the number of collecting duct cells available to respond to natriuretic peptides. Even though peptide levels are elevated, the target tissue for their action has been diminished.

In obesity, natriuretic peptide levels are paradoxically low relative to body size and cardiac load. Adipose tissue expresses high levels of NPR-C (the clearance receptor), accelerating natriuretic peptide removal from the circulation. This "natriuretic handicap" may contribute to obesity-associated hypertension and sodium retention.

Therapeutic Applications

The understanding of natriuretic peptide mechanisms has led to several therapeutic approaches. Nesiritide, a recombinant form of human BNP, was used intravenously for acute decompensated heart failure to promote natriuresis and vasodilation. See nesiritide for its clinical history and current status.

Sacubitril/valsartan (Entresto) takes a different approach. Rather than administering exogenous natriuretic peptide, it inhibits neprilysin, the enzyme that degrades endogenous ANP and BNP. By preventing breakdown, sacubitril raises circulating natriuretic peptide levels while valsartan blocks the angiotensin receptor, achieving dual inhibition of sodium retention pathways. Clinical trials have shown kidney-protective effects including reduced albuminuria and slower decline in eGFR. For details, see sacubitril/valsartan.

BNP levels are also used to guide heart failure therapy. Serial monitoring of BNP or NT-proBNP can indicate whether treatment is adequately reducing cardiac stress. For more on this approach, see natriuretic peptide-guided therapy. The broader role of these peptides in cardiac and renal protection is covered in how natriuretic peptides protect your heart and kidneys.

Limitations in the Evidence

Most of the detailed tubular transport work on ANP and sodium channels comes from animal models (particularly rat IMCD studies) and may not perfectly translate to human renal physiology. The relative contributions of hemodynamic versus tubular effects to natriuresis remain debated. Urodilatin's physiological role in humans is less well characterized than circulating ANP and BNP. The concept of natriuretic peptide resistance is widely invoked but not precisely quantified; no clinical assay measures natriuretic peptide responsiveness at the kidney level.

The Bottom Line

Natriuretic peptides (ANP, BNP, CNP) are the kidney's primary counter-regulatory system against sodium retention. ANP promotes natriuresis by inhibiting ENaC and Na+/K+-ATPase in the collecting duct, increasing GFR through arteriolar effects, and suppressing the RAAS at three points. BNP serves a dual role as both a natriuretic agent and a heart failure biomarker, complicated by renal clearance dynamics. The kidney also produces its own natriuretic peptide, urodilatin, for local sodium regulation. In heart failure, CKD, and obesity, natriuretic peptide resistance develops, allowing sodium retention despite elevated peptide levels.

Frequently Asked Questions

How do natriuretic peptides affect the kidneys?

Natriuretic peptides promote sodium and water excretion through the kidneys via multiple mechanisms. ANP inhibits sodium channels (ENaC) and sodium pumps (Na+/K+-ATPase) in the collecting duct, increases glomerular filtration rate by dilating afferent and constricting efferent arterioles, and suppresses the renin-angiotensin-aldosterone system that promotes sodium retention (Wong et al., 2017; Beltowski and Wojcicka, 2002).

What is the difference between ANP and BNP?

ANP (atrial natriuretic peptide) is a 28-amino acid peptide released from atrial heart cells in response to volume expansion. BNP (B-type natriuretic peptide) is a 32-amino acid peptide released from ventricular heart cells under pressure stress. Both promote sodium excretion through the same receptor (NPR-A), but BNP is better known clinically as a heart failure biomarker (Potter et al., 2009).

Why are BNP levels high in kidney disease?

BNP is cleared from the blood by the kidneys through the NPR-C clearance receptor and the enzyme neprilysin. When kidney function declines, BNP clearance drops and levels rise, independent of cardiac function. This makes it challenging to use BNP as a heart failure biomarker in patients with chronic kidney disease (Okamoto et al., 2019).

How do natriuretic peptides oppose the renin-angiotensin system?

Natriuretic peptides suppress the RAAS at three points: they directly inhibit renin secretion (reducing angiotensin production), directly inhibit aldosterone secretion from the adrenal cortex, and counteract angiotensin II's effects on tubular sodium reabsorption. This comprehensive suppression makes them a physiological counterbalance to the sodium-retaining RAAS (Silver, 2006).

What is urodilatin?

Urodilatin is a natriuretic peptide produced locally in the kidney's distal tubule from the same precursor as ANP. Unlike circulating ANP, urodilatin is secreted into the tubular lumen where it acts as a paracrine regulator of sodium excretion. It is resistant to degradation by neprilysin, giving it a longer local half-life than circulating natriuretic peptides (Potter et al., 2009).

Why does heart failure cause sodium retention despite high natriuretic peptide levels?

Heart failure produces natriuretic peptide resistance through multiple mechanisms: downregulation of NPR-A receptors in the kidney, increased neprilysin degradation, overwhelming activation of the RAAS, and reduced renal blood flow that limits peptide delivery to target nephrons. Despite very high circulating ANP and BNP, these compensatory mechanisms prevent adequate natriuresis.